Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of huntington disease is related to their physiological efficacy

Journal of Biological Chemistry

Volumn 287, Issue 38, 2012, Pages 31766-31782

  Martin, Bronwen ^a   Chadwick, Wayne ^a   Cong, Wei Na ^a   Pantaleo, Nick ^a   Daimon, Caitlin M ^a   Golden, Erin J ^a   Becker, Kevin G ^a   Wood III, William H ^a   Carlson, Olga D ^a   Egan, Josephine M ^a   Maudsley, Stuart ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL METHOD; BLOOD GLUCOSE; BODY WEIGHT; DISEASE PROGRESSION; ENERGY METABOLISM; ENERGY REGULATION; GENE TRANSCRIPTIONS; HORMONE LEVELS; HUNTINGTON DISEASE; INCREASED LIFE SPANS; LIFE SPAN; MOTOR CO-ORDINATION; MOTOR IMPAIRMENTS; MOUSE MODELS; NEURODEGENERATIVE DISORDERS; QUALITY OF LIFE; SIGNATURE ANALYSIS; THERAPEUTIC TREATMENTS;

BIOMECHANICS; ENERGY POLICY; GENES; GLUCOSE; INSULIN; MAMMALS; METABOLISM; MORPHOLOGY; PHYSIOLOGICAL MODELS; PHYSIOLOGY;

TRANSCRIPTION;

EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 1 TRANSFERRIN; GLUCOSE; INSULIN; INSULIN GLARGINE; LEPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENERGY METABOLISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUNTINGTON CHOREA; HYPOTHALAMUS; LIFESPAN; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; TRANSCRIPTOMICS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DRUG DESIGN; GLUCAGON-LIKE PEPTIDE 1; HUNTINGTON DISEASE; HYPOTHALAMUS; INSULIN; MALE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MODELS, NEUROLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREAS; PEPTIDES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSCRIPTION, GENETIC; VENOMS;

MUS;

EID: 84866419565     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.387316     Document Type: Article

References (55)

1. Landles, C., and Bates, G. P. (2004) Huntingtin and the molecular pathogenesis of Huntington disease. Fourth in molecular medicine review series. EMBO Rep. 5, 958-963 (Pubitemid 39534452)
2. Martin, B., Golden, E., Keselman, A., Stone, M., Mattson, M. P., Egan, J. M., and Maudsley, S. (2008) Therapeutic perspectives for the treatment of Huntington disease. Treating the whole body. Histol. Histopathol. 23, 237-250
3. Petersén, A., and Björkqvist, M. (2006) Hypothalamic- endocrine aspects in Huntington disease. Eur. J. Neurosci. 24, 961-967
4. Aziz, N. A., Swaab, D. F., Pijl, H., and Roos, R. A. (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington disease. Clinical consequences and therapeutic implications. Rev. Neurosci. 18, 223-251
5. Gaba, A. M., Zhang, K., Marder, K., Moskowitz, C. B., Werner, P., and Boozer, C. N. (2005) Energy balance in early-stage Huntington disease. Am. J. Clin. Nutr. 81, 1335-1341 (Pubitemid 41710235)
6. Van der Burg, J. M., Bacos, K., Wood, N. I., Lindqvist, A., Wierup, N., Woodman, B., Wamsteeker, J. I., Smith, R., Deierborg, T., Kuhar, M. J., Bates, G. P., Mulder, H., Erlanson-Albertsson, C., Morton, A. J., Brundin, P., Petersen, A., and Bjorkqvist, M. (2007) Increased metabolism in the R6/2 mouse model of Huntington disease. Neurobiol. Dis. 29, 41-51
7. Trejo, A., Tarrats, R. M., Alonso, M. E., Boll, M. C., Ochoa, A., and Velásquez, L. (2004) Assessment of the nutrition status of patients with Huntington disease. Nutrition 20, 192-196 (Pubitemid 38220981)
8. Popovic, V., Svetel, M., Djurovic, M., Petrovic, S., Doknic, M., Pekic, S., Miljic, D., Milic, N., Glodic, J., Dieguez, C., Casanueva, F. F., and Kostic, V. (2004) Circulating and cerebrospinal fluid ghrelin and leptin. Potential role in altered body weight in Huntington disease. Eur. J. Endocrinol. 151, 451-455 (Pubitemid 39430262)
9. Martin, B., Golden, E., Carlson, O. D., Pistell, P., Zhou, J., Kim, W., Frank, B. P., Thomas, S., Chadwick, W. A., Greig, N. H., Bates, G. P., Sathasivam, K., Bernier, M., Maudsley, S., Mattson, M. P., and Egan, J. M. (2009) Ex-endin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington disease. Diabetes 58, 318-328
10. Morton, A. J., Wood, N. I., Hastings, M. H., Hurelbrink, C., Barker, R. A., and Maywood, E. S. (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington disease. J. Neurosci. 25, 157-163 (Pubitemid 40110776)
11. Petersén, A., Gil, J., Maat-Schieman, M. L., Björkqvist, M., Tanila, H., Araújo, I. M., Smith, R., Popovic, N., Wierup, N., Norlén, P., Li, J. Y., Roos, R. A., Sundler, F., Mulder, H., and Brundin, P. (2005) Orexin loss in Huntington disease. Hum. Mol. Genet. 14, 39-47
12. Hult, S., Schultz, K., Soylu, R., and Petersén, A. (2010) Hypothalamic and neuroendocrine changes in Huntington disease. Curr. Drug Targets 11, 1237-1249
13. Björkqvist, M., Fex, M., Renström, E., Wierup, N., Petersén, A., Gil, J., Bacos, K., Popovic, N., Li, J. Y., Sundler, F., Brundin, P., and Mulder, H. (2005) The R6/2 transgenic mouse model of Huntington disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum. Mol. Genet. 14, 565-574 (Pubitemid 40309582)
14. Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E. E., Doherty, P., Davies, S. W., and Bates, G. P. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 8, 813-822 (Pubitemid 29189048)
15. Markianos, M., Panas, M., Kalfakis, N., and Vassilopoulos, D. (2005) Plasma testosterone in male patients with Huntington disease. Relations to severity of illness and dementia. Ann. Neurol. 57, 520-525 (Pubitemid 40471161)
16. Papalexi, E., Persson, A., Björkqvist, M., Petersén, A., Woodman, B., Bates, G. P., Sundler, F., Mulder, H., Brundin, P., and Popovic, N. (2005) Reduction of GnRH and infertility in the R6/2 mouse model of Huntington disease. Eur. J. Neurosci. 22, 1541-1546 (Pubitemid 41442425)
17. Kim, B. J., Zhou, J., Martin, B., Carlson, O. D., Maudsley, S., Greig, N. H., Mattson, M. P., Ladenheim, E. E., Wustner, J., Turner, A., Sadeghi, H., and Egan, J. M. (2010) Transferrin fusion technology. A novel approach to prolonging biological half-life of insulinotropic peptides. J. Pharmacol. Exp. Ther. 334, 682-692
18. Chadwick, W., Zhou, Y., Park, S. S., Wang, L., Mitchell, N., Stone, M. D., Becker, K. G., Martin, B., and Maudsley, S. (2010) Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One 5, e14352
19. Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., Houstis, N., Daly, M. J., Patterson, N., Mesirov, J. P., Golub, T. R., Tamayo, P., Spiegelman, B., Lander, E. S., Hirschhorn, J. N., Altshuler, D., and Groop, L. C. (2003) PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat. Genet. 34, 267-273 (Pubitemid 36792858)
20. Doyle, M. E., and Egan, J. M. (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113, 546-593 (Pubitemid 46365961)
21. Pérez-Tilve, D., González-Matías, L., Alvarez-Crespo, M., Leiras, R., Tovar, S., Diéguez, C., and Mallo, F. (2007) Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 56, 143-151
22. Altinova, A. E., Toruner, F., Bukan, N., Yasar, D. G., Akturk, M., Cakir, N., and Arslan, M. (2007) Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr. J. 54, 221-226 (Pubitemid 46798643)
23. Schadt, E. E., Friend, S. H., and Shaywitz, D. A. (2009) A network view of disease and compound screening. Nat. Rev. Drug. Discov. 8, 286-295
24. Martin, B., Brenneman, R., Golden, E., Walent, T., Becker, K. G., Prabhu, V. V., Wood, W., 3rd, Ladenheim, B., Cadet, J. L., and Maudsley, S. (2009) Growth factor signals in neural cells. Coherent patterns of interaction control multiple levels of molecular and phenotypic responses. J. Biol. Chem. 284, 2493-2511
25. Labudova, O., Fang-Kircher, S., Cairns, N., Moenkemann, H., Yeghiazaryan, K., and Lubec, G. (1998) Brain vasopressin levels in Down syndrome and Alzheimer disease. Brain Res. 806, 55-59 (Pubitemid 29009573)
26. Mazurek, M. F., Growdon, J. H., Beal, M. F., and Martin, J. B. (1986) CSF vasopressin concentration is reduced in Alzheimer disease. Neurology 36, 1133-1137 (Pubitemid 16038603)
27. Jarvis, K., Assis-Nascimento, P., Mudd, L. M., and Montague, J. R. (2007) β-Amyloid toxicity and reversal in embryonic rat septal neurons. Neurosci. Lett. 423, 184-188 (Pubitemid 47285476)
28. Sutherland, G., Mellick, G., Newman, J., Double, K. L., Stevens, J., Lee, L., Rowe, D., Silburn, P., and Halliday, G. M. (2008) Haplotype analysis of the IGF1-INS-TH gene cluster in Parkinson disease. Am. J. Med. Genet. B 147, 495-499 (Pubitemid 351830810)
29. Xia, X. G., Harding, T., Weller, M., Bieneman, A., Uney, J. B., and Schulz, J. B. (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 98, 10433-10438 (Pubitemid 32803037)
30. Schultz, K., Wiehager, S., Nilsson, K., Nielsen, J. E., Lindquist, S. G., Hjermind, L. E., Andersen, B. B., Wallin, A., Nilsson, C., and Petersén, A. (2009) Reduced CSF CART in dementia with Lewy bodies. Neurosci. Lett. 453, 104-106
31. Timmers, H. J., Swaab, D. F., van de Nes, J. A., and Kremer, H. P. (1996) Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington disease patients. Brain Res. 728, 141-148 (Pubitemid 26252805)
32. Jankoviç, N., Kecmanoviç, M., Dimitrijeviç, R., Keckareviç-Markoviç, M., Dobriciç, V., Keckareviç, D., Saviç Paviceviç, D., Savić Paviceviç, D., and Romaç S. (2008) HD phenocopies. Possible role of Saitohin gene. Int. J. Neurosci. 118, 391-397
33. Gossrau, G., Herting, B., Möckel, S., Kempe, A., Koch, R., Reichmann, H., and Lampe, J. B. (2006) Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson disease. J. Neural. Transm. 113, 331-337 (Pubitemid 43201099)
34. Koop, O., Timmerman, V., de Jonghe, P., Ringelstein, B., Young, P., and Kuhlenbäumer, G. (2005) Absence of mutations in the prion-protein gene in a large cohort of HMSN patients. Neuromuscul. Disord. 15, 549-551 (Pubitemid 41033009)
35. LaVaute, T., Smith, S., Cooperman, S., Iwai, K., Land, W., Meyron-Holtz, E., Drake, S. K., Miller, G., Abu-Asab, M., Tsokos, M., Switzer, R., 3rd, Grinberg, A., Love, P., Tresser, N., and Rouault, T. A. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27, 209-214 (Pubitemid 32157451)
36. Zimprich, A., Grabowski, M., Asmus, F., Naumann, M., Berg, D., Bertram, M., Scheidtmann, K., Kern, P., Winkelmann, J., Müller-Myhsok, B., Riedel, L., Bauer, M., Müller, T., Castro, M., Meitinger, T., Strom, T. M., and Gasser, T. (2001) Mutations in the gene encoding ε-sarcoglycan cause myoclonus-dystonia syndrome. Nat. Genet. 29, 66-69 (Pubitemid 32801811)
37. Tory, K., Lacoste, T., Burglen, L., Morinière, V., Boddaert, N., Macher, M. A., Llanas, B., Nivet, H., Bensman, A., Niaudet, P., Antignac, C., Salomon, R., and Saunier, S. (2007) High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis. Potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. J. Am. Soc. Nephrol. 18, 1566-1575 (Pubitemid 46717524)
38. Kim, J., Bordiuk, O. L., and Ferrante, R. J. (2011) Experimental models of HD and reflection on therapeutic strategies. Int. Rev. Neurobiol. 98, 419-481
39. Lee, S. B., Kwon, I. S., Park, J., Lee, K. H., Ahn, Y., Lee, C., Kim, J., Choi, S. Y., Cho, S. W., and Ahn, J. Y. (2010) Ribosomal protein S3, a new substrate of Akt, serves as a signal mediator between neuronal apoptosis and DNA repair. J. Biol. Chem. 285, 29457-29468
40. Lu, H., Yang, Y., Allister, E. M., Wijesekara, N., and Wheeler, M. B. (2008) The identification of potential factors associated with the development of type 2 diabetes. A quantitative proteomics approach. Mol. Cell. Proteomics 7, 1434-1451
41. Wu, L. L., Fan, Y., Li, S., Li, X. J., and Zhou, X. F. (2010) Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release. J. Biol. Chem. 285, 5614-5623
42. Pan, W., and Kastin, A. J. (2007) From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides. Peptides 28, 2411-2434 (Pubitemid 350116318)
43. Barkalifa, R., Yagil, Y., and Yagil, C. (2010) Sex-specific genetic dissection of diabetes in a rodent model identifies Ica1 and Ndufa4 as major candidate genes. Physiol. Genomics 42, 445-455
44. Hong, Y., Piao, F., Zhao, Y., Li, S., Wang, Y., and Liu, P. (2009) Subchronic exposure to arsenic decreased Sdha expression in the brain of mice. Neurotoxicology 30, 538-543
45. Chen, J., Lee, C. T., Errico, S. L., Becker, K. G., and Freed, W. J. (2007) Increases in expression of 14-3-3η and 14-3-3ζ transcripts during neuroprotection induced by Δ9-tetrahydrocannabinol in AF5 cells. J. Neurosci. Res. 85, 1724-1733 (Pubitemid 46849620)
46. Jaglin, X. H., Poirier, K., Saillour, Y., Buhler, E., Tian, G., Bahi-Buisson, N., Fallet-Bianco, C., Phan-Dinh-Tuy, F., Kong, X. P., Bomont, P., Castelnau-Ptakhine, L., Odent, S., Loget, P., Kossorotoff, M., Snoeck, I., Plessis, G., Parent, P., Beldjord, C., Cardoso, C., Represa, A., Flint, J., Keays, D. A., Cowan, N. J., and Chelly, J. (2009) Mutations in the β-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat. Genet. 41, 746-752
47. Mokhtari, D., Barbu, A., Mehmeti, I., Vercamer, C., and Welsh, N. (2009) Overexpression of the nuclear factor-κB subunit c-Rel protects against human islet cell death in vitro. Am. J. Physiol. Endocrinol. Metab. 297, E1067-E1077
48. 2 (MIF-1). Int. J. Pept. 2010
49. Niu, S. N., Huang, Z. B., Wang, H., Rao, X. R., Kong, H., Xu, J., Li, X. J., Yang, C., and Sheng, G. Q. (2011) Brainstem Hap1-Ahi1 is involved in insulin-mediated feeding control. FEBS Lett. 585, 85-91
50. Pers, T. H., Hansen, N. T., Lage, K., Koefoed, P., Dworzynski, P., Miller, M. L., Flint, T. J., Mellerup, E., Dam, H., Andreassen, O. A., Djurovic, S., Melle, I., Børglum, A. D., Werge, T., Purcell, S., Ferreira, M. A., Kouskoumvekaki, I., Workman, C. T., Hansen, T., Mors, O., and Brunak, S. (2011) Meta-analysis of heterogeneous data sources for genome-scale identification of risk genes in complex phenotypes. Genet. Epidemiol. 35, 318-322
51. Head, G. A., and Mayorov, D. N. (2006) Imidazoline receptors, novel agents, and therapeutic potential. Cardiovasc. Hematol. Agents Med. Chem. 4, 17-32 (Pubitemid 43796697)
52. Scuteri, A., Ravasi, M., Pasini, S., Bossi, M., and Tredici, G. (2011) Mesenchymal stem cells support dorsal root ganglion neurons survival by inhibiting the metalloproteinase pathway. Neuroscience 172, 12-19
53. Kos, K., and Wilding, J. P. H. (2010) SPARC. A key player in the pathologies associated with obesity and diabetes. Rev. Endocrinol. 6, 225-235
54. Schilling, G., Coonfield, M. L., Ross, C. A., and Borchelt, D. R. (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington disease transgenic mouse model. Neurosci. Lett. 315, 149-153 (Pubitemid 33079072)
55. Hickey, M. A., Zhu, C., Medvedeva, V., Franich, N. R., Levine, M. S., and Chesselet, M. F. (2012) Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington disease. Mol. Cell. Neurosci. 49, 149-157